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Introduction
============

The profound roles that TGFβ plays during embryogenesis, adult tissue homeostasis, and disease pathogenesis necessitate deeper understanding of mechanisms that regulate this signaling pathway. Signaling occurs via the TGFβ type II receptor (TβRII) that trans-phosphorylates TβRI, also known as activin receptor-like kinase (ALK) 5. Activated ALK5 phosphorylates receptor-regulated Smads (Smad2 and Smad3), promotes their association with Smad4, and leads to regulation of transcription ([@bib6]).

Smad7, a negative regulator of TGFβ/Smad signaling, is an immediate early gene target of the pathway (for review see [@bib7]). Smad7 binds to ALK5, competing with Smad2/3 phosphorylation and mediating receptor ubiquitination, mechanisms which link to the process of TGFβ receptor internalization and lysosomal degradation ([@bib5]).

We have identified gene targets of Smad signaling ([@bib9]). A highly regulated gene, *SNF1LK* (*sucrose nonfermented 1-like kinase*) or *salt-inducible kinase 1* (*SIK1*, hereby abbreviated as SIK), encodes a serine/threonine kinase. SIK is one of 14 AMP-activated protein kinases that can be phosphorylated by the tumor suppressor LKB1 ([@bib1]). SIK expression is induced during cardiogenesis and skeletal muscle differentiation ([@bib17]) or in adrenal glands, leading to steroidogenesis ([@bib16]).

We uncover a new functional role of SIK in the TGFβ pathway. SIK induction is necessary for physiological TGFβ signaling. Ubiquitin promotes association of SIK to Smad7, which down-regulates ALK5. Thus, SIK defines a new negative-feedback loop initiated by incoming Smad signals.

Results and discussion
======================

TGFβ induces SIK in a Smad-dependent manner
-------------------------------------------

We have reported Smad4-dependant gene profiles in response to TGFβ1 or bone morphogenetic protein (BMP) 7 using human breast carcinoma MDA-MB-468 cells that lack both *Smad4* gene copies ([@bib9]). After reconstitution with Smad4, TGFβ1 or BMP7 rapidly induced *SIK* mRNA, followed by slow decrease ([Fig. 1, A and B](#fig1){ref-type="fig"}). In human HaCaT keratinocytes, TGFβ1 induced and sustained *SIK* mRNA and protein levels ([Fig. 1, C and D](#fig1){ref-type="fig"}; and Fig. S1 A, available at <http://www.jcb.org/cgi/content/full/jcb.200804107/DC1>). Endogenous TGFβ1-induced SIK protein showed punctate nuclear, cytoplasmic, and peripheral localization ([Fig. 1 E](#fig1){ref-type="fig"}). *SIK* represents a new gene target of TGFβ/BMP7 Smad signaling. Interestingly, the *Caenorhabditis elegans* orthologue of SIK, Kin-29, regulates chemosensory neuronal signaling and body size, a process which is dependent on TGFβ/Smad ([@bib10]; [@bib12]), which is in agreement with our data.

![**Smad signaling induces endogenous *SIK*.** (A) cDNA microarray analysis of *SIK* mRNA in Smad4-deficient MDA-MB-468 cells after infection with adenovirus expressing LacZ or Smad4 and stimulation with 2 ng/ml TGFβ1 or 300 ng/ml BMP7. Normalized mean expression values with error bars from triplicate microarray expressions are shown (arbitrary units). (B and C) Semiquantitative RT-PCR analysis of *SIK* and *GAPDH* mRNA in MDA-MB-468 cells as in A (B) or in response to 2 ng/ml TGFβ1 in HaCaT cells (C). Amplified cDNA sizes are in bp. (D) SIK and α-tubulin loading control protein profiles in response to 5 ng/ml TGFβ1 in HaCaT cells. Protein sizes are in kilodaltons. (E) Induction of nuclear and cytoplasmic levels of endogenous SIK by 5 ng/ml TGFβ1 in HaCaT cells (bar, 10 μm).](jcb1820655f01){#fig1}

SIK down-regulates activated ALK5
---------------------------------

Gain-of-function experiments with transfected SIK showed specific down-regulation of ALK5 after TGFβ1 stimulation, whereas minor effects were scored without stimulation ([Fig. 2 A](#fig2){ref-type="fig"}). SIK did not down-regulate Smad7 or GFP (Fig. S1 B), excluding translational inhibition or induction of proteolysis.

![**SIK down-regulates activated ALK5.** (A) Immunoblot of ALK5 expressed in COS1 cells together with TβRII and stimulation or not with 2 ng/ml TGF-β1 for 12 h in the absence or presence of increasing wild-type GFP-SIK amounts. (B and C) Pulse-chase analysis of CA-ALK5, KR-ALK5, and CIN85 in the absence (−) or presence (+) of cotransfected SIK (S). A 30-min pulse was followed by chase for the indicated times. Treatment with proteasomal (LLnL 200 μM; S + L) or lysosomal (chloroquine 400 μM; S + Q) inhibitor during the chase is shown in C. Radioactive quantitation of ALK5 or CIN85 protein is plotted relative to the pulse signal. Representative data from three independent repeats are shown. Protein autoradiograms are shown below each graph. (D) Immunoblot of CA-ALK5 in COS1 cells cotransfected with wild-type and mutant SIK constructs. (E, top) quantitative real-time RT-PCR analysis of *SIK* mRNA in HaCaT cells after transfection with control (siLuc) and specific (siSIK) siRNAs and 8 h of stimulation with 5 ng/ml TGFβ1. Mean fold induction of TGFβ-stimulated *SIK* (black bars) relative to unstimulated levels (gray bars) are plotted, with standard errors determined from triplicate samples. (E, bottom) Immunoblot of endogenous SIK, ALK5, and α-tubulin loading control in HaCaT total cell lysates (TCL) prepared as per mRNA analysis. (F) Mv1Lu cells transfected with control (siLuc) or specific (siSIK) siRNA were incubated with radio-TGFβ1 before cross-linking and incubation at 37°C for the indicated time periods. Cell surface receptor autoradiograms show the three TGF-β receptors (TβR) marked as type I, II, and III, and the unbound ligand (TGFβ) migrating at the bottom. Protein sizes are in kilodaltons. Black lines indicate that intervening lanes have been spliced out.](jcb1820655f02){#fig2}

SIK affected ALK5 turnover as it reduced the half-life of a constitutively active (CA) ALK5 from 5.5 to 2.8 h without affecting a KR- (kinase-dead) ALK5 or an unrelated adaptor protein CIN85 ([Fig. 2 B](#fig2){ref-type="fig"}). Proteasomal (LLnL) and lysosomal (chloroquine) inhibitors stabilized the ALK5 levels in the presence of SIK ([Fig. 2 C](#fig2){ref-type="fig"}), suggesting both proteasomal and lysosomal mechanisms in ALK5 down-regulation by SIK.

SIK has an N-terminal kinase domain with lysine 56 binding to ATP and a central ubiquitin-associated (UBA) domain, which regulates conformation and kinase activity ([@bib8]). A catalytically inactive (K56R) SIK or a deletion mutant lacking the UBA domain (ΔUBA) failed to down-regulate CA-ALK5 ([Fig. 2 D](#fig2){ref-type="fig"}). This suggests that both catalytic activity and UBA domain of SIK affect ALK5 turnover.

RNAi against SIK significantly enhanced endogenous ALK5 levels ([Fig. 2 E](#fig2){ref-type="fig"}). Increased presence of endogenous cell surface receptors measured with chemically cross-linked radioligand upon depletion of SIK further strengthened this evidence ([Fig. 2 F](#fig2){ref-type="fig"}, 0 h). Thus, endogenous SIK must regulate total ALK5 levels, which also affects cell surface receptor numbers, available for signaling. Receptor down-regulation was also slower after SIK RNAi. Significantly higher ligand-bound receptor levels were observed for up to 1 h of internalization compared with control ([Fig. 2 F](#fig2){ref-type="fig"}).

Because proteasomal and lysosomal inhibitors block ALK5 degradation ([Fig. 2 C](#fig2){ref-type="fig"}), we suggest that ALK5 turnover takes place in lysosomes. Proteasomes might promote trafficking to the lysosome, as has already been established for the EGF receptor ([@bib11]; [@bib3]). How proteasomes regulate TGF-β receptor internalization and degradation remains unclear.

SIK associates and cooperates with Smad7 for ALK5 down-regulation
-----------------------------------------------------------------

Down-regulation of ALK5 is mediated by Smad7 (for review see [@bib7]). We reasoned that SIK could associate directly with ALK5 or Smad7. Coimmunoprecipitation assays showed that SIK formed complexes with both ALK5 and Smad7 ([Fig. 3, A and B](#fig3){ref-type="fig"}). To detect SIK--ALK5 complexes, we had to achieve low SIK expression and high CA-ALK5 levels, which resulted in active ALK5 signaling with small effects on receptor down-regulation. SIK bound stronger to the Smad7 linker and C-terminal (Mad homology 2) domains than to its N-terminal domain ([Fig. 3 B](#fig3){ref-type="fig"}). When endogenous human ALK5, Smad7, and SIK were immunoprecipitated from HaCaT lysates, SIK coprecipitated primarily with Smad7 and weakly with ALK5 ([Fig. 3 C](#fig3){ref-type="fig"}), confirming the evidence with transfected proteins. Thus, protein complexes between endogenous SIK, Smad7, and ALK5 occur in vivo.

![**SIK associates and cooperates with Smad7 to down-regulate ALK5.** (A) Coimmunoprecipitation of CA-ALK5 with wild-type (WT) SIK and TCL controls for SIK. Low levels of SIK coexpressed with high levels of CA-ALK5 allowed detection of SIK--ALK5 complexes with only small effects on receptor down-regulation. (B) Coimmunoprecipitation of wild-type SIK with wild type and various Smad7 domains (C, C-terminal; Link, linker; N, N-terminal). TCL controls for SIK and immunoglobulin chains (Ig) are shown. (C) Coimmunoprecipitation of endogenous SIK with endogenous ALK5 and Smad7. HaCaT cell lysates, pretreated with 50 μM MG132 and 5 ng/ml TGFβ1 overnight, were immunoprecipitated with anti-ALK5, anti-Smad7, and anti-SIK (988) antibodies, followed by immunoblotting with anti-SIK (988) antibody. TCL immunoblots with the three antibodies demonstrate specificity of each antiserum. Asterisks indicate specific protein bands and sizes are in kilodaltons. The top left panel (Mock and ALK5) was exposed four times longer than the top right panel (Smad7 and SIK). (D) Triple confocal immunofluorescence analysis of wild-type SIK, CA-ALK5, and wild-type Smad7 in transfected Mv1Lu cells. Insets show high magnifications of peripheral clusters just below the plasma membrane (bar, 10 μm). (E) SIK represses synergistically with Smad7 CAGA~12~ promoter induction by 0.5 ng/ml TGFβ1 for 6 h in HepG2 cells transfected with empty vector or Flag-SIK and Flag-Smad7. Normalized promoter activity is plotted as mean values from triplicate determinations with standard error bars. (F) Depletion of endogenous Smad7 stabilizes the CA-ALK5 receptor and wild-type SIK. Immunoblot of HEK293T cell extracts after transient transfection with shRNA vector pSuper-Smad7 or its empty (mock) version together with increasing amounts (triangles) of GFP-SIK and constant amount of CA-ALK5. The asterisks indicate nonspecific protein bands. Protein sizes are shown in kilodaltons.](jcb1820655f03){#fig3}

Smad7 resides in the nucleus and moves to the cytoplasm in response to TGF-β (for review see [@bib7]). SIK also resides in both nucleus and cytoplasm, and its localization is regulated by hormones in adrenal cells or by the 14--3-3 adaptor ([@bib16]; [@bib2]). In transfected TGFβ-sensitive Mv1Lu cells, SIK localized in nuclei and cytoplasm with pronounced punctate distribution proximal to the plasma membrane ([Fig. 3 D](#fig3){ref-type="fig"}), which is similar to endogenous SIK ([Fig. 1 E](#fig1){ref-type="fig"}). Colocalization of SIK, CA-ALK5, and Smad7 was primarily observed in peripheral clusters ([Fig. 3 D](#fig3){ref-type="fig"}, insets). Thus, SIK, Smad7, and ALK5 must form complexes in cytoplasmic regions proximal to the plasma membrane.

To verify the cooperation of Smad7 and SIK in negatively regulating TGFβ signaling, we measured the effects of SIK and Smad7 on the transcriptional induction of a Smad3/Smad4-specific promoter-reporter, CAGA~12~, by TGFβ1 ([Fig. 3 E](#fig3){ref-type="fig"}). SIK enhanced the inhibitory effect of Smad7 by more than twofold. Knockdown of endogenous Smad7 stabilized and rescued CA-ALK5 down-regulation by SIK, even though Smad7 depletion led to increased SIK levels ([Fig. 3 F](#fig3){ref-type="fig"}). Thus, SIK mediates down-regulation of signaling ALK5 receptor in a Smad7-dependent manner.

Ubiquitin and the UBA domain modulate ALK5 regulation by SIK
------------------------------------------------------------

We examined whether ubiquitin affected the ability of SIK to facilitate ALK5 degradation ([Fig. 4 A](#fig4){ref-type="fig"}). Ubiquitin significantly enhanced the potency of CA-ALK5 down-regulation by SIK. A K48R ubiquitin mutant completely blocked this down-regulation. This implies that polyubiquitin chain formation via lysine 48 affects ALK5 degradation, which is compatible with a proteasome-dependent mechanism and inhibition of ALK5 degradation by LLnL ([Fig. 2 D](#fig2){ref-type="fig"}).

![**Role of ubiquitin and the UBA domain of SIK in ALK5 down-regulation.** (A) Immunoblot of CA-ALK5 in the presence of increasing doses of WT GFP-SIK and coexpression of WT or K48R mutant ubiquitin. (B) Confocal immunofluorescence analysis of wild-type or mutant SIK proteins cotransfected with HA-ubiquitin in Mv1Lu cells. Insets show higher magnifications of peripheral clusters below the plasma membrane (bar, 10 μm). (C) SIK lysate was mixed briefly with lysate for ubiquitinated proteins before immunoprecipitation. SIK mutant proteins were immunoprecipitated (anti-Flag) and ubiquitinated proteins are detected (anti-HA immunoblot). Total SIK levels (bottom) and immunoglobulin heavy chain (Ig) are shown. (D) Coimmunoprecipitation of wild-type Smad7 with wild-type myc-SIK or UBA deletion mutant in the absence or presence of ubiquitin. The asterisk indicates a slow migrating SIK species, possibly representing ubiquitinated SIK. TCL controls of SIK variants, the immunoglobulin heavy chain (Ig), and protein sizes in kilodaltons are shown. Black lines indicate that intervening lanes have been spliced out.](jcb1820655f04){#fig4}

We examined SIK localization in relation to ubiquitin in Mv1Lu cells ([Fig. 4 B](#fig4){ref-type="fig"}). SIK distributed in nuclei, cytoplasm, and prominent peripheral structures, SIK-K56R showed more cytoplasmic enrichment, and both colocalized with cytoplasmic ubiquitin clusters. SIK lacking its UBA domain showed no colocalization, as it distributed diffusely in the cytoplasm, suggesting that SIK-ubiquitin clusters depend on the integrity of the UBA domain. These punctate structures were also enriched in 19S and 20S proteasomes (unpublished data).

We then expressed SIK and ubiquitin in different pools of cells before immunoprecipitation to measure association of SIK with ubiquitinated proteins but not SIK ubiquitination, per se ([Fig. 4 C](#fig4){ref-type="fig"} and Fig. S2 A, available at <http://www.jcb.org/cgi/content/full/jcb.200804107/DC1>). SIK readily coprecipitated ubiquitinated proteins of diverse sizes, confirming that they were distinct from ubiquitinated SIK. Wild-type and SIK-K56R bound to ubiquitinated proteins, whereas SIK-ΔUBA or a mutant lacking both kinase and UBA domains (ΔN) did not, suggesting that the SIK UBA domain is needed for binding to polyubiquitinated proteins ([Fig. 4 C](#fig4){ref-type="fig"}). C-terminal deletion of SIK, after its UBA domain, had no effect on binding ubiquitinated proteins ([Fig. 4 C](#fig4){ref-type="fig"}). Thus, SIK can associate with ubiquitinated proteins in cells.

Obvious ubiquitinated protein candidates to which SIK could bind were ALK5 and Smad7. Accordingly, the SIK--Smad7 complex was enhanced by coexpressing ubiquitin, whereas deletion of the UBA domain of SIK prohibited such enhancement ([Fig. 4 D](#fig4){ref-type="fig"}). A slow migrating SIK form was obvious in complex with Smad7 ([Fig. 4 D](#fig4){ref-type="fig"}, asterisk), which may represent ubiquitinated SIK. In contrast, neither ubiquitin nor UBA domain deletion had any effect on SIK--ALK5 complexes (Fig. S2 B). Ubiquitin therefore enhances association between SIK and Smad7, and the SIK UBA domain mediates formation of this ternary complex.

The SIK UBA domain was recently shown to not bind ubiquitin but to modulate SIK kinase activity in vitro ([@bib8]). We also failed in demonstrating in vitro binding of recombinant mono- or oligoubiquitin chains to SIK (unpublished data). SIK immunopurified from mammalian cells clearly bound to ubiquitinated proteins via its UBA domain ([Fig. 4 C](#fig4){ref-type="fig"} and Fig. S2 A). This could reflect an in vivo modification or the requirement for another binding protein. Further studies will reveal the mechanism by which ubiquitin and the SIK UBA domain regulate its own function.

SIK negatively regulates TGFβ signaling
---------------------------------------

Stimulation of cells after endogenous SIK depletion enhanced the potency of TGF-β signaling ([Fig. 5, A and B](#fig5){ref-type="fig"}). Signaling was assessed by measuring mRNA levels of well characterized TGFβ gene targets, representing three distinct physiological programs: the fibrotic program (*plasminogen activator inhibitor 1* \[*PAI-1*\], TGFβ inducible), the cytostatic program (cell cycle inhibitors *p21* and *p15*, TGFβ inducible; transcriptional regulators *c-myc* and *Id2*, TGFβ repressible), and the negative-feedback program (*Smad7*, TGFβ-inducible; [Fig. 5 B](#fig5){ref-type="fig"} and Fig. S3, available at <http://www.jcb.org/cgi/content/full/jcb.200804107/DC1>). We also confirmed that SIK knockdown enhanced the magnitude of endogenous PAI-1 and p21 protein accumulation in response to TGFβ1 ([Fig. 5 C](#fig5){ref-type="fig"}). Finally, protein levels and pericellular localization of fibronectin, another TGFβ gene target from the fibrotic program, augmented significantly after depleting SIK ([Fig. 5, D and E](#fig5){ref-type="fig"}). Thus, induction of SIK by TGFβ represents a central step in negative regulation of TGFβ signaling.

![**Endogenous SIK negatively regulates endogenous TGFβ signaling.** (A) Immunoblot of endogenous SIK and α-tubulin loading control in HaCaT TCL after transfection with control (siLuc) and specific (siSIK) siRNAs and 12 h of stimulation with 5 ng/ml TGFβ1. The asterisk marks a nonspecific protein band. (B) Quantitative real-time RT-PCR analysis in HaCaT cells treated with siRNAs as in A and stimulated with 5 ng/ml TGFβ1 for 6 h (*PAI-1* and *p21*) or 8 h (*Smad7* and *p15*). Mean fold induction of TGFβ-stimulated mRNA levels (black bars) relative to unstimulated levels (gray bars) are plotted, with standard errors determined from triplicate or quadruplicate samples. Asterisks indicate significant difference (*t* test: P \<0.05) in mRNA levels in cells transfected with siLuc versus siSIK siRNA and stimulated with TGFβ1. (C) Immunoblot of endogenous PAI-1, p21, and α-tubulin loading control in HaCaT cells treated as in A and stimulated with 5 ng/ml TGFβ1 for the indicated times. Black lines indicate that intervening lanes have been spliced out. (D) Immunofluorescence analysis of endogenous fibronectin in HaCaT cells treated as in A and stimulated with 5 ng/ml TGFβ1 for 12 h (bar, 10 μm). (E) Immunoblot of endogenous fibronectin and α-tubulin loading control in the same experimental setup as in D. Protein sizes are shown in kilodaltons. (F) Model of SIK as a negative regulator of TGFβ signaling. TGFβ receptors activate nuclear Smad complexes with transcription factors (TF) to mediate gene responses (green circles). Genes of the cytostatic (proliferation), differentiation, ECM, and negative-feedback programs are listed. Negative-feedback loop protein products assemble the machinery that inhibits signaling. SIK associates with the TβRI and Smad7, promoting internalization and termination of receptor signaling.](jcb1820655f05){#fig5}

The identification of *SIK* as an immediate early gene induced by the Smad pathway led to important new insights into how TGFβ receptor signaling is negatively regulated ([Fig. 5 F](#fig5){ref-type="fig"}). SIK joins Smad7 in the negative-feedback loop of TGFβ signaling (for review see [@bib7]). SIK and Smad7 interact, and ubiquitin enhances their complex. SIK also binds to ALK5 and down-regulates the receptor in a Smad7-dependent manner. This model applies to various epithelial cell models that are highly sensitive to TGFβ including keratinocytes and lung cells. Our study emphasizes the role of ubiquitin and proteasomes in regulation of TGFβ signaling by SIK. Our data also support a role for the kinase activity of SIK ([Fig. 2 D](#fig2){ref-type="fig"}). This offers the first evidence for a kinase/ubiquitin binding protein being involved in the down-regulation of a signaling receptor. Identifying possible SIK substrates within the ALK5--Smad7 complex and explaining their functional role in regulation of TGFβ signaling will be important. We provide evidence for lysosomal degradation of TGFβ receptors ([Fig. 2 C](#fig2){ref-type="fig"}). This is a relatively unexplored step during TGFβ receptor internalization. TGFβ receptor ubiquitination and proteasomal degradation is often reported (for review see [@bib7]). A lysosomal pathway of receptor-ligand degradation would better fit to the classical mechanisms of receptor internalization and degradation. During this process, ubiquitin and proteasomes might act as intermediate processors of TGFβ receptor trafficking from the plasma membrane to the lysosome.

Evolutionary conservation of SIK from humans to *C. elegans*, and functional conservation of SIK as a regulator of homeostatic (this study) and developmental ([@bib12]) pathways guided by TGFβ signaling opens new territories for exploration of such pathways across species. Characterizing the role of the *Drosophila melanogaster* SIK orthologue will greatly benefit this cause.

Because SIK is activated by the tumor suppressor kinase LKB1 ([@bib1]), our study suggests a role of LKB1 in processes of TGFβ signaling and receptor down-regulation. Thus, SIK being a component of the TβR--Smad7 complex provides a nodal point for crosstalk of the TGFβ pathway with LKB1 or AMP-activated protein kinase pathways. SIK therefore opens a new window for the elucidation of the process of down-regulation of serine/threonine kinase receptors.

Materials and methods
=====================

Reagents
--------

HaCaT keratinocytes, MDA-MB-468, HEK293T and HepG2 carcinoma, COS1 and Mv1Lu cells, and culture conditions were as previously described ([@bib9]; [@bib13]). Recombinant TGF-β1 was obtained from PeproTech. Anti--β-tubulin (T8535) and anti-Flag (M5) antibodies were obtained from Sigma-Aldrich; anti-GFP (A11122) from Invitrogen; anti--PAI-1 and anti-p21 (Cip1/WAF1) from BD Biosciences; anti-HA (Y-11), anti-TβRI (V-22), and anti--α-tubulin (TU-02) from Santa Cruz Biotechnology, Inc.; rabbit polyclonal anti--human SIK (988, raised against peptide CEEQDTQESLPSSTGRR mapping C-terminally from the UBA domain), anti-Smad7, and mouse monoclonal anti-myc (9E10) were made in house; rabbit polyclonal anti-CIN85(CT) was from I. Dikic (Goethe University, Frankfurt, Germany); secondary antibodies coupled to HRP from GE Healthcare; secondary antibodies coupled to FITC and TRITC from Dako; Alexa Fluor 546 from Invitrogen; and AMCA7 (7-amino-4-methylcoumarin-3-acetic acid) from Jackson ImmunoResearch Laboratories.

Human *SIK*-specific siRNA, ON-TARGET plus SMARTpool reagent L-003959-00, and control siRNA against the *luciferase* reporter vector pGL2 (X65324) were from Thermo Fisher Scientific. An EST clone BG719047 of human SIK complete cDNA was obtained from H. Takemori and M. Okamoto (National Institute of Biomedical Innovation, Osaka, Japan). The cDNA was fused to a Flag, 6myc, and GFP creating pcDNA3-Flag-hSIK, pcDNA3-6myc-hSIK, and pEGFP-hSIK. The SIK ATP binding site mutant K56R was created by the Quick-Change mutagenesis kit (Stratagene). Deletion mutants SIK-ΔUBA, SIK (K56R)-ΔUBA, SIK-ΔC, and SIK-ΔN were created using a PCR-based strategy and were subcloned in pcDNA3-Flag and pEGFP. DNA constructs were sequence verified.

Vectors pcDNA3-ALK5(wt)-HA (wild-type receptor with C-terminal hemagglutinin tag), pcDNA3-ALK5(CA)-HA (CA T204D mutant receptor), pcDNA3-ALK5(KR)-HA (kinase dead ATP-binding site mutant receptor), pcDNA3-Flag-Smad7, pcDNA3-6myc-Smad7, pcDNA3-6myc-Smad7 deletion mutants (N-, Linker, C-), pcDNA3-HA-ubiquitin, and pcDNA3-HA-ubiquitin(K48R) and gene reporters pGL3-CAGA~12~-luc and pCMV-βgal were previously described ([@bib13]); pcDNA3-CIN85 was from I. Dikic (Goethe University, Frankfurt, Germany); pcDNA3-TβRI(wt)-Flag and pcDNA3-TβRII(wt)-Flag were from E.B. Leof (Mayo Clinic, Rochester, MN); pSuper-Smad7 expressing a short hairpin RNA against mouse and human Smad7 mRNAs was made by ligating the Smad7-specific hairpin (5′-GATCCCC[GAGGCTGTGTTGCTGTGAA]{.ul}TT CAAGAGA[TTCACAGCAACACAGCCTC]{.ul}TTTTTGGAAA-3′; underlined sequences show the hairpin stem) to pSuper (a gift from R. Agami, Netherlands Cancer Institute, Amsterdam, Netherlands; [@bib4]).

Transient transfections
-----------------------

HaCaT cells were transfected with siRNAs via Lipofectamine 2000 (Invitrogen) or SiLentFect (Bio-Rad Laboratories), COS1 and Mv1Lu cells via Lipofectamine, and HEK293T and HepG2 cells via calcium phosphate as previously described ([@bib9]). 24 h after transfection, cells were stimulated with TGF-β1 as indicated in the figures.

RT-PCR
------

Total HaCaT or MDA-MB-468 RNA was analyzed by quantitative or semiquantitative RT-PCR as previously described ([@bib15]). PCR primers are listed in [Tables I](#tbl1){ref-type="table"} and [II](#tbl2){ref-type="table"}, and *glyceraldehyde-3′-phosphate dehydrogenase* (*GAPDH*) was the reference gene. A two-tailed paired Student\'s *t* test (significance at P \< 0.05) was used to compare TGFβ1-inducible levels after control or SIK-specific knockdown in triplicate (*PAI-1*, *p21*, and *p15*) or quadruplicate (*Smad7*) determinations.

###### Human oligonucleotide primers used for RT-PCR

  Gene                   Primer Sequence                  Strand   Product size   Temperature   PCR cycle   Reference
  ---------------------- -------------------------------- -------- -------------- ------------- ----------- -----------
                                                                   *bp*           °C                        
  *SIK*                  5′-GTCTGGGCGCACCTTTAGCA-3′       \+       387            62            27          NM_173354
                         5′-CAGCCTTTCGCCCAGTCTTT-3′       −                                                 
  *IDB2*                 5′-ACGACCCGATGAGCCTGCTA-3′       \+       213            55            24          [@bib9]
                         5′-TCCTGGAGCGCTGGTTCTG-3′        −                                                 
  *CDKN1A     (p21)*    5′-CTGCCCAAGCTCTACCTTCC-3′       \+       123            57            28          [@bib9]
                         5′-CAGGTCCACATGGTCTTCCT-3′       −                                                 
  *c-MYC*                5′-ACCCGGACGACGAGACCTTCATCA-3′   \+       683            63            23          [@bib9]
                         5′-GGGGCTGGTGCATTTTCGGTTGTT-3′   −                                                 
  *MADH7     (Smad7)*   5′-CAGATTCCCAACTTCTTCTG-3′       \+       533            53            27          [@bib9]
                         5′-GTTGAAGATGACCTCCAGCC-3′       −                                                 
  *GAPDH*                5′-ATCACTGCCACCCAGAAGAC-3′       \+       443            57            22          [@bib9]
                         5′-ATGAGGTCCACCACCCTGTT-3′       −                                                 

A previously published reference or the NCBI database accession number is indicated.

###### Human oligonucleotide primers used for quantitative real-time RT-PCR

  Gene                   Primer Sequence                       Strand   Product size   Temperature   Reference
  ---------------------- ------------------------------------- -------- -------------- ------------- -----------------
                                                                        *bp*           *°C*          
  *SIK*                  5′-CAACCTGGGCGACTACGATGAGCA-3′        \+       167            60            NM_173354
                         5′-GGGCGCACTGGGCATTCCGATACT-3′        −                                     
  *CDKN1B     (p15)*    5′-TGGACCTGGTGGCTACGAAT-3′(+)         \+       150            60            [@bib15]
                         5′-AGGGCCTAAGTTGTGGGTTCA-3′(−)        −                                     
  *CDKN1A     (p21)*    5′-CTGCCCAAGCTCTACCTTCC-3′(+)         \+       123            60            [@bib15]
                         5′-CAGGTCCACATGGTCTTCCT-3′(−)         −                                     
  *PAI-1*                5′-GAGACAGGCAGCTCGGATTC-3′            \+       101            60            ENST00000223095
                         5′-GGCCTCCCAAAGTGCATTAC-3′            −                                     
  *MADH7     (Smad7)*   5′-ACCCGATGGATTTTCTCAAACC-3′          \+       85             60            ENST00000262158
                         5′-GCCAGATAATTCGTTCCCCCT-3′           −                                     
  *GAPDH*                5′-GGAGTCAACGGATTTGGTCGTA-3′(+)       \+       78             60            [@bib15]
                         5′-GGCAACAATATCCACTTTACCAGAGT-3′(−)   −                                     

A previously published reference, the NCBI database accession number, or the Ensembl database transcript (ENST) number is indicated.

Promoter-reporter assays
------------------------

HepG2 cells transfected with the Smad3-responsive reporter pGL3-CAGA~12~-luc for 36 h before stimulation with TGF-β1 for 6 h were analyzed with the enhanced luciferase assay kit (BD Biosciences). Normalized promoter activity is plotted as mean values from triplicate determinations with standard deviations.

Immunoblotting, immunoprecipitation, and ubiquitination assays
--------------------------------------------------------------

SDS-PAGE, immunoblot, coimmunoprecipitation, pulldown, and ubiquitination analysis was as previously described ([@bib9]; [@bib13]). For efficient detection of endogenous SIK, HaCaT cells were pretreated with 50 μM MG132 (EMD) for 6 h at 37°C. For pulse-chase analysis, a 30 min pulse with ^35^S-methionine/cysteine was followed by a chase, as indicated in the Figures and as previously described ([@bib13]). Cells treated with proteasomal inhibitor, calpain inhibitor I (*N*-Acetyl-Leu-Leu-norleucinal, LLnL; Roche) or lysosomal inhibitor chloroquine (Sigma-Aldrich) were also analyzed. To measure association between SIK and ubiquitinated proteins, HEK293T cells were transfected with Flag-SIK in one plate and HA-ubiquitin in another and treated with proteasomal inhibitors, MG132, or LLnL. Individual cell lysates were combined before immunoprecipitation.

Confocal microscopy
-------------------

Approximately 70% confluent transfected Mv1Lu monolayers were analyzed by immunofluorescence 24 h after transfection as previously described ([@bib9]). Nuclei were counterstained with DAPI or propidium iodide. A confocal microscope (Axiovert 200 M; Carl Zeiss, Inc.) equipped with LSM 510 laser was used with the 63×/0.75 NA objective lens (Carl Zeiss, Inc.) and photographing at ambient temperature in the presence of immersion oil. Images acquired with a charge-coupled device camera (C4742-95; Hamamatsu Photonics) and the acquisition software QED Camera Plug-in v.1.1.6 (QED Imaging Inc.) were reduced in memory content using Photoshop 6.0 (Adobe), without additional processing.

Receptor affinity cross-linking
-------------------------------

Mv1Lu cells incubated on ice with iodinated TGF-β1 were cross-linked, as previously described ([@bib14]), and shifted to 37°C, as indicated in the figure, before SDS-PAGE and autoradiography.

Online supplemental material
----------------------------

Fig. S1 shows endogenous SIK protein levels in response to TGFβ1 and the lack of effect of SIK expression on GFP or Smad7 levels. Fig. S2 shows interaction of SIK with ubiquitinated proteins and interaction between SIK and ALK5 in presence of ubiquitin. Fig. S3 shows mRNA profiles of *Smad7*, *p21*, *c-myc*, and *Id2* during a time course in response to TGFβ1 in control cells or after SIK knockdown. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.200804107/DC1>.
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